Company Overview
Snapshot
Founded in October 2023 by Liron Ben-Bashat Bergman, David Salton, Ron Beloosesky, and Gilad Cohen, Hemo AI operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing an AI-powered IV blood monitoring medical device.
Business overview
Hemo AI is developing an automated, wearable IV blood monitoring system designed to provide real-time alerts for bleeding and sepsis. The company's core technology integrates data aggregation with AI analysis to enhance patient care and revolutionize traditional monitoring methods. Hemo AI's solution is ideal for use in various medical environments, including hospitals, ICUs, ambulances, and field hospitals, serving the broader Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Hemo AI's primary focus?
- Hemo AI is focused on developing an AI-powered IV blood monitoring medical device that provides real-time alerts for conditions such as bleeding and sepsis.
- When was Hemo AI founded?
- Hemo AI was founded in October 2023.
- Who are the founders of Hemo AI?
- Hemo AI was founded by Liron Ben-Bashat Bergman, David Salton, Ron Beloosesky, and Gilad Cohen.
- What markets does Hemo AI's technology target?
- Hemo AI's system is designed for use in hospitals, ICUs, ambulances, and field hospitals, aiming to improve patient care through advanced monitoring.
- What is the current stage of Hemo AI's funding?
- Hemo AI is currently in the Pre-Funding stage, having not yet raised any external capital as of May 2025.